ANNX vs. BMEA, PEPG, HRTX, TBPH, FULC, CRBP, MREO, ESPR, SLRN, and NGNE
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Biomea Fusion (BMEA), PepGen (PEPG), Heron Therapeutics (HRTX), Theravance Biopharma (TBPH), Fulcrum Therapeutics (FULC), Corbus Pharmaceuticals (CRBP), Mereo BioPharma Group (MREO), Esperion Therapeutics (ESPR), Acelyrin (SLRN), and Neurogene (NGNE). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Biomea Fusion has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.
Annexon received 12 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 73.33% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
In the previous week, Annexon had 29 more articles in the media than Biomea Fusion. MarketBeat recorded 29 mentions for Annexon and 0 mentions for Biomea Fusion. Annexon's average media sentiment score of 1.00 beat Biomea Fusion's score of 0.39 indicating that Biomea Fusion is being referred to more favorably in the media.
Biomea Fusion presently has a consensus target price of $53.25, indicating a potential upside of 335.05%. Annexon has a consensus target price of $14.14, indicating a potential upside of 226.62%. Given Annexon's higher probable upside, research analysts plainly believe Biomea Fusion is more favorable than Annexon.
96.7% of Biomea Fusion shares are held by institutional investors. 26.3% of Biomea Fusion shares are held by insiders. Comparatively, 19.1% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Biomea Fusion's return on equity of -56.52% beat Annexon's return on equity.
Summary
Annexon beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
